Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| FULC | PRESS-RELEASE | neutral | 3/10 | Fulcrum Therapeutics (FULC) announced a partnership with MedicAlert Foundation and the Sickle Cell Disease Association o | Mar 19, 2026 |
| INMB | PRESS-RELEASE | bullish | 7/10 | INmune Bio highlighted positive biomarker-enriched Phase 2 MINDFuL trial results for XPro1595 in Alzheimer’s disease dur | Mar 19, 2026 |
| CMMB | PRESS-RELEASE | bullish | 8/10 | Chemomab Therapeutics reported its full-year and Q4 2025 financial results, highlighted by a successful FDA End-of-Phase | Mar 19, 2026 |
| COLL | PRESS-RELEASE | bullish | 8/10 | Collegium Pharmaceutical is acquiring AZSTARYS, a differentiated ADHD treatment, from Corium Therapeutics for $650 milli | Mar 19, 2026 |
| IFRX | PRESS-RELEASE | bullish | 7/10 | InflaRx reported financial results for 2025, highlighted by a narrow improvement in net loss to €45.6M from €46.1M in 20 | Mar 19, 2026 |
| ANVS | PRESS-RELEASE | neutral | 4/10 | Annovis Bio has partnered with NeuroRPM to integrate an FDA-cleared AI-powered digital biomarker platform into its ongoi | Mar 19, 2026 |
| BIIB | PRESS-RELEASE | bullish | 8/10 | Biogen announced upcoming presentation of late-breaking Phase 2 (Part A) results from the AMETHYST study of litifilimab | Mar 19, 2026 |
| TGTX | PRESS-RELEASE | bullish | 7/10 | TG Therapeutics announced a new $750 million senior secured credit facility with Blue Owl Capital, using $250 million to | Mar 19, 2026 |
| ACRV | PRESS-RELEASE | bullish | 8/10 | Acrivon Therapeutics reported financial results for Q4 and full year 2025, showing reduced net losses compared to the pr | Mar 19, 2026 |
| LRMR | PRESS-RELEASE | mixed | 7/10 | Larimar Therapeutics reported Q4 and full-year 2025 financial results, highlighted by Breakthrough Therapy Designation f | Mar 19, 2026 |
| NRXP | PRESS-RELEASE | neutral | 3/10 | NRx Pharmaceuticals announced it will host a conference call to discuss its fiscal year 2025 financial results and provi | Mar 19, 2026 |
| OKYO | PRESS-RELEASE | neutral | 4/10 | OKYO Pharma announced that Chief Development Officer and Director Gary Jacob acquired 30,980 additional shares at $1.59, | Mar 19, 2026 |
| CRDF | PRESS-RELEASE | mixed | 5/10 | Cardiff Oncology announced preclinical data showing its PLK1 inhibitor onvansertib enhances the antitumor activity of tr | Mar 19, 2026 |
| PTHS | PRESS-RELEASE | bullish | 8/10 | Pelthos Therapeutics reported strong Q4 and full-year 2025 financial results, driven by 28% quarter-over-quarter growth | Mar 19, 2026 |
| BKHAU | PRESS-RELEASE | neutral | 4/10 | Vesicor Therapeutics, the proposed de-SPAC merger target of Black Hawk Acquisition Corp. (BKHAU), has appointed Michael | Mar 18, 2026 |
| RVPH | PRESS-RELEASE | bearish | 6/10 | Reviva Pharmaceuticals (RVPH) announced the pricing of a public offering of 6,666,667 shares of common stock and accompa | Mar 18, 2026 |
| MRKR | PRESS-RELEASE | mixed | 6/10 | Marker Therapeutics reported financial results for 2025, highlighting a net loss increase to $12.2 million despite lower | Mar 18, 2026 |
| XOMA | PRESS-RELEASE | neutral | 3/10 | XOMA Royalty Corporation declared quarterly cash dividends for its Series A and Series B Cumulative Preferred Stock, wit | Mar 18, 2026 |
| RVPH | PRESS-RELEASE | neutral | 4/10 | Reviva Pharmaceuticals (RVPH) announced plans for a public offering of common stock and warrants, with proceeds intended | Mar 18, 2026 |
| SPRO | PRESS-RELEASE | neutral | 4/10 | Spero Therapeutics announced it will release its Q4 and full-year 2025 financial results on March 26, 2026, after market | Mar 18, 2026 |
| FDMT | PRESS-RELEASE | neutral | 3/10 | 4D Molecular Therapeutics reported full-year 2025 financial results and provided operational updates. The press release | Mar 18, 2026 |
| PROK | PRESS-RELEASE | mixed | 6/10 | ProKidney reported financial results for 2025, highlighting a reduction in net loss to $151.6 million from $163.3 millio | Mar 18, 2026 |
| ONMD | PRESS-RELEASE | mixed | 5/10 | OneMedNet Corporation (ONMD) announced a strategic collaboration with Navidence to integrate Navidence's Computable Oper | Mar 18, 2026 |
| RNXT | PRESS-RELEASE | neutral | 5/10 | RenovoRx (RNXT) announced an oversubscribed private placement expected to raise approximately $10 million in gross proce | Mar 18, 2026 |
| DWTX | PRESS-RELEASE | mixed | 6/10 | Dogwood Therapeutics reported fourth quarter and full-year 2025 financial results, showing a reduced net loss due to low | Mar 18, 2026 |
| DERM | PRESS-RELEASE | neutral | 3/10 | Journey Medical Corporation (DERM) announced it will release its year-end 2025 financial results on March 25, 2026, foll | Mar 18, 2026 |
| GANX | PRESS-RELEASE | bullish | 7/10 | Gain Therapeutics presented new Phase 1b clinical data for GT-02287 in Parkinson’s disease at AD/PD 2026, showing biomar | Mar 18, 2026 |
| SXTP | PRESS-RELEASE | neutral | 4/10 | Sixty Degrees Pharmaceuticals submitted a New Dietary Ingredient Notification (NDIN) to the FDA for a dietary supplement | Mar 18, 2026 |
| CINGW | PRESS-RELEASE | mixed | 6/10 | Cingulate Inc. reported its Q4 and full-year 2025 financial results, highlighted by a $12 million PIPE financing, U.S. a | Mar 18, 2026 |
| BCTXL | PRESS-RELEASE | mixed | 5/10 | BriaCell Therapeutics will present four posters at the 2026 AACR Annual Meeting, including Phase 3 quality-of-life data | Mar 18, 2026 |